Our Investor Proposition

Stock Information

CEO Thomas Lingelbach comments on Valneva‘s Half Year 2024 Results

Upcoming Events

August 12, 2025

H1 2025 Financial Results

November 20, 2025

9M 2025 Financial Results

Jefferies 2024 Global Healthcare Conference

Valneva presented at the Jefferies London Healthcare Conference.

Access the webcast of a fireside chat with our CEO here.

Quick Links

Check out our 2024 Annual Business Report

View More

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France

T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

June 26, 2025

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

June 25, 2025

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

June 5, 2025

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

View More